Business, energy, technology, markets and global industry news from Business News Today

ALK inhibitor

PharmaDeviceNews ALK inhibitor
Representative image of an oncologist reviewing lung cancer scans with a patient, reflecting Nuvalent’s neladalkib FDA Priority Review and the growing race to develop targeted therapies for ALK-positive non-small cell lung cancer.
Pharma & Biotech

Nuvalent’s ALK inhibitor gets Priority Review as lung cancer treatment sequencing evolves

Nuvalent’s neladalkib has FDA Priority Review in ALK-positive lung cancer. Find out why resistance and brain metastases drive the story.

Read More
Representative image of an oncology consultation involving lung scan review, reflecting how Xcovery Holdings’ Ensacove launch and EVERSANA’s commercialization support could influence patient access in ALK-positive non-small cell lung cancer care.
Pharma & Biotech

Can EVERSANA help Xcovery turn Ensacove into a serious ALK-positive lung cancer contender?

ALK lung cancer has strong therapies already. Xcovery’s Ensacove now faces the harder test of access, adoption, and differentiation.

Read More